We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

InDevR Signs Global Distributors

InDevR Signs Global Distributors

InDevR Signs Global Distributors

InDevR Signs Global Distributors

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "InDevR Signs Global Distributors"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Virus Counter represents a significant technology shift that will dramatically streamline research and development efforts for vaccine manufacturers, pharmaceutical and biotechnology companies and researchers worldwide. This proprietary, patent-pending technology will allow scientists to expedite the vaccine development process and greatly improve time to market.

Michael Minard, InDevR's Director of Business Development, said the Virus Counter will be actively marketed to scientists in India, China, Japan, Korea, Belgium, Luxembourg, the Netherlands, the United Kingdom and the United States via select distributors. Minard adds, "This rapid growth and acceptance by distributors reflects the level of excitement about the new technology."

"Current testing methodologies are inconsistent, sometimes unreliable and time consuming. Compared to old methods -- which can take days to weeks to complete - the Virus Counter provides scientists with accurate virus quantification within minutes," said Kathy L. Rowlen, PhD, InDevR's CEO and Chief Science Officer. "We are honored to have these very talented and knowledgeable distributors help us bring the Virus Counter to scientific communities throughout the world."

Rowlen said agreements have been executed with AR Brown Co., Ltd., to market the Virus Counter in Japan; Pharmatech Inc., in Korea; Applikon Biotechnology Inc.-US for the United States of America; Applikon Biotechnology B.V. for the countries of Belgium, Luxemburg, Netherlands and the UK; Automed Systems Pvt. Ltd. for the nation of India; and HuaYue Enterprise Holdings Ltd. for the country of China.

Bhanu Prakash, CEO of Automed Group of Companies, India said, "The Virus Counter provides a proven, reliable and simple method to quantify viruses in a fraction of time required to conduct a traditional plaque assay. India has a very important and active vaccine research community which will benefit from this exciting technology. We're very pleased to offer the Virus Counter to scientists in India."

"We are delighted to bring this product to market in China. We have a number of important customers who are actively seeking solutions to their virus quantification challenges. Our customer base is excited about this novel instrument," said Rolyn Lou, General Sales Manager, Biopharmaceutical Division, for HuaYue.